Cubist Systematic Strategies’s Centessa Pharmaceuticals CNTA Stock Holding History

Cubist Systematic Strategies’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$2.52M	Sell	103,909 -172,543	-62%	-$3.07M	0.01%	1419
2025 Q2	$3.63M	Buy	+276,452	New	+$3.5M	0.02%	1217
2025 Q1	–	Sell	-45,885	Closed	-$769K	–	2947
2024 Q4	$769K	Sell	45,885 -88,235	-66%	-$1.46M	﹤0.01%	1956
2024 Q3	$2.14M	Buy	134,120 +108,047	+414%	+$1.32M	0.01%	1389
2024 Q2	$235K	Sell	26,073 -46,536	-64%	-$441K	﹤0.01%	2447
2024 Q1	$820K	Buy	72,609 +67,785	+1,405%	+$642K	﹤0.01%	2307
2023 Q4	$38.4K	Buy	+4,824	New	+$32.3K	﹤0.01%	3298
2022 Q4	–	Sell	-1,000	Closed	-$4K	–	4287
2022 Q3	$4K	Buy	1,000 +432	+76%	+$1.98K	﹤0.01%	4327
2022 Q2	$3K	Buy	+568	New	+$3.63K	﹤0.01%	4308
2022 Q1	–	Sell	-632	Closed	-$7K	–	3583
2021 Q4	$7K	Buy	632 +432	+216%	+$5.81K	﹤0.01%	3401
2021 Q3	$3K	Sell	200 -200	-50%	-$4.14K	﹤0.01%	2920
2021 Q2	$9K	Buy	+400	New	+$9.4K	﹤0.01%	2866

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Cubist Systematic Strategies's CNTA Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Centessa Pharmaceuticals (CNTA) stake by 62% in Q3 2025, selling an estimated $3.07M and leaving 103,909 shares worth $2.52M. The position accounts for 0.01% of the portfolio, ranked #1419.

Cubist Systematic Strategies first reported a position in CNTA in Q2 2021 and has held it in 12 quarters since. The position peaked at $3.63M in Q2 2025. 125 funds tracked by Wall St. Rank hold CNTA as of Q3 2025.

Cubist Systematic Strategies held 103,909 shares of Centessa Pharmaceuticals worth $2.52M as of Q3 2025.
Cubist Systematic Strategies sold 172,543 Centessa Pharmaceuticals shares in Q3 2025, an estimated $3.07M.
Centessa Pharmaceuticals made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1419 holding.
Cubist Systematic Strategies first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 12 quarters since.
Cubist Systematic Strategies's Centessa Pharmaceuticals position peaked at $3.63M in Q2 2025.
125 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.